Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


02.09.2019

1 Gastroenterol Hepatol
1 Gastroenterology
2 Gut
2 Hepatology
1 Int J Cancer
1 Int J STD AIDS
2 J Hepatol
2 J Med Virol
2 J Viral Hepat
2 J Virol
5 PLoS One
3 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Gastroenterol Hepatol

  1. SICRAS MAINAR A, Navarro Artieda R, Hernandez I, Morillo R, et al
    Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
    Gastroenterol Hepatol. 2019 Aug 23. pii: S0210-5705(19)30138.
    PubMed     Text format     Abstract available


    Gastroenterology

  2. TSENG TC, Liu CJ, Hsu CY, Hong CM, et al
    High Level of Hepatitis B Core-related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
    Gastroenterology. 2019 Aug 27. pii: S0016-5085(19)41248.
    PubMed     Text format     Abstract available


    Gut

  3. LIEM KS, Fung S, Wong DK, Yim C, et al
    Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Gut. 2019 Aug 28. pii: gutjnl-2019-318981. doi: 10.1136/gutjnl-2019-318981.
    PubMed     Text format     Abstract available

  4. XIAO Y, Sun K, Duan Z, Liu Z, et al
    Quasispecies characteristic in "a" determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case-control study.
    Gut. 2019 Aug 24. pii: gutjnl-2019-318278. doi: 10.1136/gutjnl-2019-318278.
    PubMed     Text format     Abstract available


    Hepatology

  5. BARRE T, Protopopescu C, Bani-Sadr F, Piroth L, et al
    Elevated fatty liver index as a risk factor for all-cause mortality in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30914.
    PubMed     Text format     Abstract available

  6. MAYA S, Ploss A
    Master of disguise: hepatitis delta virus packaging and spread facilitated by diverse viral envelope proteins.
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30922.
    PubMed     Text format     Abstract available


    Int J Cancer

  7. YU J, Ding WB, Wang MC, Guo XG, et al
    Plasma Circular RNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma: A Large-Scale, Multicenter Study.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32647.
    PubMed     Text format     Abstract available


    Int J STD AIDS

  8. CAGATAY AA, Deniz R, Gozukucuk R, Ozbek E, et al
    Acute hepatitis and pancytopenia related to non-typhoidal salmonella infection in a human immunodeficiency virus-infected patient.
    Int J STD AIDS. 2019 Aug 27:956462419863227. doi: 10.1177/0956462419863227.
    PubMed     Text format    


    J Hepatol

  9. NEUMANN-HAEFELIN C
    Paving the way for T cell-based immunotherapies in chronic hepatitis E.
    J Hepatol. 2019 Aug 22. pii: S0168-8278(19)30427.
    PubMed     Text format    

  10. DE HAAN LR, van Golen RF
    Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
    J Hepatol. 2018 Oct 4. pii: S0168-8278(18)32382.
    PubMed     Text format    


    J Med Virol

  11. LEE KC, Lin CL, Hsu CW, Chang ML, et al
    Decreasing seroprevalence of anti-hepatitis D virus antibodies in the antiviral era with inverse association with hepatitis B virus DNA, Taiwan, 2006 - 2019.
    J Med Virol. 2019 Aug 30. doi: 10.1002/jmv.25582.
    PubMed     Text format     Abstract available

  12. JANG ES, Kim KA, Kim YS, Kim IH, et al
    Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: an emphasis on the pretreatment NS5A resistance-associated substitution test.
    J Med Virol. 2019 Aug 26. doi: 10.1002/jmv.25575.
    PubMed     Text format     Abstract available


    J Viral Hepat

  13. LIMOTHAI U, Chuaypen N, Poovorawan K, Chotiyaputta W, et al
    Baseline and kinetics of serum HBV RNA predict response to pegylated interferon-based therapy in patients with HBeAg-negative chronic hepatitis B.
    J Viral Hepat. 2019 Aug 25. doi: 10.1111/jvh.13195.
    PubMed     Text format     Abstract available

  14. CATLETT B, Lamoury FMJ, Bajis S, Hajarizadeh B, et al
    Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study.
    J Viral Hepat. 2019 Aug 26. doi: 10.1111/jvh.13196.
    PubMed     Text format     Abstract available


    J Virol

  15. CHEN TI, Hsu YK, Chou CY, Chen YH, et al
    Hepatitis C Virus NS3 Protein Plays a Dual Role in WRN-Mediated Repair of Non-Homologous End Joining.
    J Virol. 2019 Aug 28. pii: JVI.01273-19. doi: 10.1128/JVI.01273.
    PubMed     Text format     Abstract available

  16. JOHNSON J, Freedman H, Logan M, Wong JAJ, et al
    A recombinant HCV genotype 1a E1/E2 envelope glycoprotein vaccine elicits antibodies that differentially neutralize closely related 2a strains through interactions of the N-terminal hypervariable region 1 of E2 with scavenger receptor B1.
    J Virol. 2019 Aug 28. pii: JVI.00810-19. doi: 10.1128/JVI.00810.
    PubMed     Text format     Abstract available


    PLoS One

  17. UYEI J, Taddei TH, Kaplan DE, Chapko M, et al
    Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study.
    PLoS One. 2019;14:e0221614.
    PubMed     Text format     Abstract available

  18. CHUGH Y, Dhiman RK, Premkumar M, Prinja S, et al
    Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    PLoS One. 2019;14:e0221769.
    PubMed     Text format     Abstract available

  19. PEREZ AB, Chueca N, Macias J, Pineda JA, et al
    Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
    PLoS One. 2019;14:e0221231.
    PubMed     Text format     Abstract available

  20. HUANG YJ, Yang SS, Yeh HZ, Chang CS, et al
    Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B.
    PLoS One. 2019;14:e0221958.
    PubMed     Text format     Abstract available


  21. Retraction: The Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection and Cirrhosis.
    PLoS One. 2019;14:e0222176.
    PubMed     Text format    


    Vaccine

  22. XIA R, Sun S, Shen M, Zhang L, et al
    Targeted hepatitis E vaccination for women of childbearing age is cost-effective in China.
    Vaccine. 2019 Aug 20. pii: S0264-410X(19)31040.
    PubMed     Text format     Abstract available

  23. PARK BJ, Ahn HS, Han SH, Go HJ, et al
    Evaluation of the protective effects of a nanogel-based vaccine against rabbit hepatitis E virus.
    Vaccine. 2019 Aug 24. pii: S0264-410X(19)31093.
    PubMed     Text format     Abstract available

  24. NGUYEN TT, Choi JA, Kim JS, Park H, et al
    Skin immunization with third-generation hepatitis B surface antigen using microneedles.
    Vaccine. 2019 Aug 26. pii: S0264-410X(19)31100.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: